The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

Original title: “This week in charts: Moderna’s massive stock run”

Inconsistent reporting at a Pennsylvania site affected microbiological analyses of components and drug products that analytical testing service provider Eurofins ran for customers.

Original title: “FDA issues warning over Eurofins’ selective recording that 'compromises' data”

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

Original title: “Belgian startup revives Galapagos CAR-T research”

AstraZeneca will tap AI-focused insitro to find new targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, following the Phase 3 failure of its Ionis-partnered Wainua in transthyretin-mediated amyloid cardiomyopathy.

Original title: “AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro”